PDCD1 and non-small cell lung carcinoma: According to the results of several interventional studies reported to date, anti-PD-1/PD-L1 antibody monotherapy and the combination of nivolumab plus ipilimumab have demonstrated a certain level of safety with no apparent increase in the frequency or severity of irAEs, even in NSCLC patients with PS 2.